Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.98 USD
Change Today -0.08 / -3.88%
Volume 659.3K
ATRS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

antares pharma inc (ATRS) Snapshot

Open
$2.04
Previous Close
$2.06
Day High
$2.07
Day Low
$1.98
52 Week High
04/16/15 - $3.04
52 Week Low
09/30/14 - $1.82
Market Cap
306.4M
Average Volume 10 Days
515.3K
EPS TTM
$-0.25
Shares Outstanding
154.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ANTARES PHARMA INC (ATRS)

Related News

No related news articles were found.

antares pharma inc (ATRS) Related Businessweek News

View More BusinessWeek News

antares pharma inc (ATRS) Details

Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company’s injection products include OTREXUP, a pre-filled methotrexate syringe with Vibex self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Tjet/Zomajet, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle. Its transdermal gel products comprise Gelnique 3%, an oxybutynin gel product for the treatment of overactive bladder; and Elestrin, a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. The company also offers OTREXUP, an injection for subcutaneous use indicated for adults with severe active RA, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis, as well as Vibex auto injectors. In addition, it is developing Vibex QS T for testosterone replacement therapy for men who have testosterone deficiency; Vibex QS M with an undisclosed drug for treatment of a CNS indication; and disposable pen injectors. Antares Pharma, Inc. has collaborative and license agreements with Ferring Pharmaceuticals BV; Teva Pharmaceutical Industries, Ltd.; JCR Pharmaceuticals Co., Ltd.; Actavis, Inc.; Meda Pharmaceuticals, Inc.; Pfizer Inc; Population Council; and LEO Pharma, Inc. The company was founded in 1979 and is headquartered in Ewing, New Jersey.

93 Employees
Last Reported Date: 03/12/15
Founded in 1979

antares pharma inc (ATRS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $292.9K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $43.8K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $391.1K
Compensation as of Fiscal Year 2014.

antares pharma inc (ATRS) Key Developments

Antares Pharma Inc. Announces Executive Changes

Antares Pharma Inc. announced the appointment of Peter J. Graham, Esq., to the position of Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer and Corporate Secretary. Mr. Graham will report to Eamonn P. Hobbs, President and Chief Executive Officer. The Company also announced the departure of Jennifer Evans Stacey, Esq., the Company's Senior Vice President, General Counsel, Human Resources and Secretary and Chief Compliance Officer. Mr. Graham was most recently Executive Vice President, General Counsel, Chief Compliance Officer and Global Human Resources of Delcath Systems Inc. Prior to Delcath, Mr. Graham was Vice President, General Counsel and a member of the Executive Committee of ACIST Medical Systems Inc.

Antares Pharma Inc. Announces Additional Update to QuickShot Testosterone Program

Antares Pharma Inc. announced that it has received a written update from the U.S. Food and Drug Administration related to its clinical development program for QuickShot Testosterone that the company believes is consistent with its previously disclosed interpretation of the advice letter received from FDA in January 2015. As previously disclosed, the company received an advice letter from FDA in January 2015 regarding various clinical, CMC (Chemistry, Manufacturing and Controls) and user study submissions made by the Company through November 2014, and the Company responded to that advice letter in March 2015. The Company believes that with the update just received from FDA, there is an agreed upon path forward for the completion of an additional study to support the filing of a New Drug Application for QS T. Based on the number of subjects in previous studies and in the current ongoing phase 3 study, the Company will need approximately 70 additional subjects exposed to QS T for six months, resulting in approximately 350 subjects exposed to QS T, with 200 subjects exposed for six months and 100 subjects exposed for a year. The company is now finalizing the protocol for the study and expects to initiate the trial in the third quarter of 2015.

Antares Pharma Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 12:30 PM

Antares Pharma Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 12:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: James E. Fickenscher, Chief Financial Officer and Senior Vice President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATRS:US $1.98 USD -0.08

ATRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioject Medical Technologies Inc $0.05 USD 0.00
Hospira Inc $89.42 USD +0.19
Mylan NV $57.24 USD +0.89
West Pharmaceutical Services Inc $60.61 USD +0.80
Ypsomed Holding AG SFr.107.00 CHF +0.10
View Industry Companies
 

Industry Analysis

ATRS

Industry Average

Valuation ATRS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.2x
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANTARES PHARMA INC, please visit www.antarespharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.